Brokerages predict that Epizyme Inc (NASDAQ:EPZM) will report sales of $2.15 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Epizyme’s earnings, with estimates ranging from $100,000.00 to $4.20 million. Epizyme reported sales of $10.00 million in the same quarter last year, which indicates a negative year-over-year growth rate of 78.5%. The firm is scheduled to announce its next quarterly earnings report on Friday, August 3rd.
On average, analysts expect that Epizyme will report full year sales of $4.83 million for the current year, with estimates ranging from $300,000.00 to $10.00 million. For the next year, analysts forecast that the firm will post sales of $24.55 million per share, with estimates ranging from $300,000.00 to $125.24 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Epizyme.
Epizyme (NASDAQ:EPZM) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.05. During the same quarter in the previous year, the business posted ($0.56) EPS.
EPZM has been the subject of a number of research reports. BidaskClub raised shares of Epizyme from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 24th. Leerink Swann set a $24.00 target price on shares of Epizyme and gave the stock a “buy” rating in a report on Tuesday, April 24th. ValuEngine lowered shares of Epizyme from a “sell” rating to a “strong sell” rating in a report on Monday, April 9th. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Thursday, March 15th. Finally, SunTrust Banks reissued a “buy” rating and issued a $27.00 price objective on shares of Epizyme in a report on Wednesday, March 14th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $23.00.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Palo Alto Investors LP grew its holdings in shares of Epizyme by 0.5% in the first quarter. Palo Alto Investors LP now owns 6,895,075 shares of the biopharmaceutical company’s stock valued at $122,388,000 after purchasing an additional 34,232 shares during the period. Palo Alto Investors LLC grew its holdings in shares of Epizyme by 7.2% in the fourth quarter. Palo Alto Investors LLC now owns 6,860,843 shares of the biopharmaceutical company’s stock valued at $86,104,000 after purchasing an additional 462,547 shares during the period. BlackRock Inc. grew its holdings in shares of Epizyme by 17.1% in the fourth quarter. BlackRock Inc. now owns 3,965,391 shares of the biopharmaceutical company’s stock valued at $49,766,000 after purchasing an additional 579,662 shares during the period. Redmile Group LLC grew its holdings in shares of Epizyme by 4.5% in the first quarter. Redmile Group LLC now owns 2,011,989 shares of the biopharmaceutical company’s stock valued at $35,713,000 after purchasing an additional 86,300 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Epizyme by 56.4% in the fourth quarter. Millennium Management LLC now owns 996,687 shares of the biopharmaceutical company’s stock valued at $12,508,000 after purchasing an additional 359,547 shares during the period. 85.22% of the stock is owned by hedge funds and other institutional investors.
Epizyme opened at $13.55 on Monday, Marketbeat.com reports. Epizyme has a 52-week low of $11.15 and a 52-week high of $21.40. The firm has a market cap of $941.56 million, a PE ratio of -6.22 and a beta of 2.09.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Get a free copy of the Zacks research report on Epizyme (EPZM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.